Bendamustine in Metastatic Breast Cancer: An Old Drug in New Design.
The goal of treatment for patients with advanced breast cancer is to prolong survival, control symptoms, and reduce disease-related complications. Despite the introduction of many cytotoxic agents during the past decade, only modest improvement in survival in metastatic breast cancer has been achieved. In order to improve this situation, new cytotoxic drugs as well as molecule-targeted agents are now under investigation. Bendamustine is a bifunctional alkylating agent with cytotoxic activity against several types of solid tumors. In the search for new anthracycline-free combinations, taxanes and alkylating agents might be worth investigating, in order to reduce cardiac toxicity. In this article, we reviewed the latest information regarding antitumor activity, toxicity, pharmacokinetics, and clinical application of bendamustine as a cytotoxic agent in metastatic breast cancer.
Pirvulescu
Cristina
C
German Breast Group, GBG Forschungs GmbH, Neu-Isenburg, Germany.
von Minckwitz
Gunter
G
Loibl
Sibylle
S
Anticancer Drugs. 2007 Sep;18(8):963-8
17667603
J Cancer Res Clin Oncol. 1998;124(11):627-32
9860292
J Cancer Res Clin Oncol. 2002 Feb;128(2):111-3
11862482
J Clin Oncol. 2006 Dec 1;24(34):5381-7
17135639
Geburtshilfe Frauenheilkd. 1991 May;51(5):383-6
1869008
Cancer. 2004 Jan 1;100(1):44-52
14692023
Anticancer Drugs. 2005 Sep;16(8):871-7
16096436
J Cancer Res Clin Oncol. 2000 Jan;126(1):41-7
10641748
Ann Oncol. 2007 Dec;18(12):1981-4
17872900
Ann Oncol. 2000 Jun;11(6):729-34
10942063
Breast Care (Basel). 2008;3(2):87-92
21373210
Pneumologie. 1998 Oct;52(10):570-3
9847635
J Cancer Res Clin Oncol. 2002 May;128(5):271-8
12029443
Leuk Lymphoma. 2004 Jul;45(7):1429-36
15359644
J Cancer Res Clin Oncol. 2006 Apr;132(4):205-12
16402269
Zentralbl Chir. 1998;123 Suppl 5:156-8
10063603
Clin Cancer Res. 2008 Jan 1;14(1):309-17
18172283
Biochem Pharmacol. 2003 Sep 1;66(5):711-24
12948851
Leukemia. 2002 Oct;16(10):2096-105
12357363